Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Shares of Novavax Inc. NVAX rose 1.96% to $8.60 Wednesday, on what proved to be an all-around positive trading session for ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...